Researchers have identified the soluble WNT pathway inhibitor SCLEROSTIN as an independent risk factor for all-cause #mortality in patients after kidney transplantation.
600 stable renal transplant recipients were followed for all-cause mortality for 3 years.
Sclerostin is an independent risk factor for all-cause mortality in kidney transplant recipients.
Zeng S et al., Clin Exp Nephrology (2020). Click link for full text.
Biomedica Sclerostin ELISA: https://www.bmgrp.com/product/cardiovascular/sclerostin-elisa-human-sost-biomedica/
√ HIGH QUALITY – fully validated assay according to ICH/FDA/EMEA guidelines
√ LOW SAMPLE VOLUME – only 20 µl sample / well
√ EASY – convenient ready to use protocol
√ MOST REFERENCED Sclerostin ELISA
Also available: Bioactive Sclerostin ELISA https://www.bmgrp.com/product/cardiovascular/biomedica-bioactive-sclerostin-elisa-human-sost/
√ specific antibodies targeting the receptor binging region
The new intact FGF23 ELISA was mentioned in the most recent Biocompare newsletter as a featured product. Check out the drug discovery and development newsletter to learn more.
FGF23 (intact) human ELISA
Features and Benefits
• RELIABLE and FULLY VALIDATED for plasma samples – according to ICH Q2
• SERUM, URINE and CC SUPERNATANT are compatible with this ELISA
• FAST ONE-STEP ELISA – only 3.5 h total incubation time
• PLASMA BASED STANDARDS and CONTROLS INCLUDED – for biologically reliable data
• CHARACTERIZED MONOCLONAL ANTIBODIES – high specificity and sensitivity guaranteed
• GOOD CORRELATION with existing ELISA methods
Why FGF23 ELISA from Biomedica?
√ Proprietary products – developed and manufactured in our European facilities
√ Excellent stability in all matrices after sample collection
√ CE registration in progress
Please click below for:
– Assay Validation Data
– Instruction For Use
– Biomedica FGF23 Info Leaflet
– Product Website
Related Product:
FGF23 (C-terminal) ELISA
|
||
|
||